Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
Holding IRWD?
Track your performance easily
IRWD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.06 - $15.70
Previous Close$4.45
Volume11.01M
Average Volume (3M)1.75M
Market Cap
$620.91M
Enterprise Value$1.15B
Total Cash (Recent Filing)$88.21M
Total Debt (Recent Filing)$614.87M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Feb 13, 2025EPS Estimate
$0.06Last Dividend Ex-Date
Apr 02, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding160,028,388
10 Day Avg. Volume3,444,845
30 Day Avg. Volume1,750,415
Standard Deviation0.11
R-Squared0.04
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-2.28
Price to Sales (P/S)1.64
Price to Cash Flow (P/CF)15.70
P/FCF Ratio15.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.03
Enterprise Value/Gross Profit0.74
Enterprise Value/Ebitda12.43
Forecast
1Y Price Target
$11.40Price Target Upside156.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Ironwood Pharma News
PremiumCompany Announcements
Ironwood Pharmaceuticals Reports Q3 2024 Performance
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe maximum amount on the revolving credit facility has been increased to $550M, which may improve financial flexibility.
Market PositionIRWD's Apraglutide trial had three times the number of patients compared to the competitor's trial, which could satisfy FDA's requirements.
Regulatory ApprovalThere is a high likelihood of first cycle approval for Apraglutide as one successful Phase 3 trial is typically sufficient for FDA approval.
Bears Say
Drug Development And PipelineFailure to exercise the CNP-104 option could raise concerns around lack of pipeline catalysts looking ahead.
Financial PerformanceThe company's total debt stands at approximately $600MM, resulting in a net debt to EBITDA ratio of about 6 times.
Sales And RevenueInvestors are focusing on LINZESS sales, which have been guided down twice this year due to pricing pressure from higher-than-expected Medicaid utilization trends.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
IRWD FAQ
What was Ironwood Pharma’s price range in the past 12 months?
Ironwood Pharma lowest stock price was $3.06 and its highest was $15.70 in the past 12 months.
What is Ironwood Pharma’s market cap?
Currently, no data Available
When is Ironwood Pharma’s upcoming earnings report date?
Ironwood Pharma’s upcoming earnings report date is Feb 13, 2025 which is in 53 days.
How were Ironwood Pharma’s earnings last quarter?
Ironwood Pharma released its earnings results on Nov 07, 2024. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.072 by -$0.052.
Is Ironwood Pharma overvalued?
According to Wall Street analysts Ironwood Pharma’s price is currently Undervalued.
Does Ironwood Pharma pay dividends?
Ironwood Pharma pays a Notavailable dividend of $2.285 which represents an annual dividend yield of N/A. See more information on Ironwood Pharma dividends here
What is Ironwood Pharma’s EPS estimate?
Ironwood Pharma’s EPS estimate is $0.06.
How many shares outstanding does Ironwood Pharma have?
Ironwood Pharma has 160,028,380 shares outstanding.
What happened to Ironwood Pharma’s price movement after its last earnings report?
Ironwood Pharma reported an EPS of $0.02 in its last earnings report, missing expectations of $0.072. Following the earnings report the stock price went down -7.54%.
Which hedge fund is a major shareholder of Ironwood Pharma?
Among the largest hedge funds holding Ironwood Pharma’s share is Royce & Associates LLC. It holds Ironwood Pharma’s shares valued at 3M.
---
Ironwood Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.40 (156.18% Upside)
$11.40 (156.18% Upside)
Blogger Sentiment
Bearish
IRWD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 933.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $44.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.67%
Trailing 12-Months
Company Description
Ironwood Pharma
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.
---
IRWD Company Deck
---
IRWD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted robust prescription growth for LINZESS and significant progress with apraglutide, indicating a strong market position and potential for future growth. However, considerable pricing pressures on LINZESS and program adjustments in the pipeline present notable challenges.Read More>---
IRWD Stock 12 Month Forecast
Average Price Target
$11.40
▲(156.18% Upside)
Technical Analysis
Best Analysts Covering IRWD
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-34.24%
assigned a buy rating 2 days ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -34.24% per trade.
---